Alzheimer Europe has published a new edition of its “Dementia in Europe” policy magazine, in an electronic format. The first section of the magazine includes a closing article on the EPAD project in which Alzheimer Europe has been involved. Our co-leads Craig Ritchie and Serge Van der Geyten have been interviewed and reflect on the…
At an online European Parliament workshop hosted by Deirdre Clune MEP (Ireland), Alzheimer Europe launched a new report “Data Sharing in Dementia Research”, which reviews recent changes in EU research policy and sets out recommendations to improve data sharing in dementia research. In this report, Alzheimer Europe evaluates the legal and policy landscapes that dementia…
On 17 February, we were pleased to hold the first local EPAD community meeting among the Scottish research sites, collaborators, academics and scientists who have been involved in the EPAD Longitudinal Cohort Study (LCS) throughout the IMI funded period and now continue to contribute to the study locally. The first local EPAD community meeting focused…
On 1 February, the members of the Neuronet (Efficiently Networking European Neurodegeneration Research) programme announced the launch of a pan-European Knowledge Base which brings together key information about the 18 projects of the Innovative Medicines Initiative (IMI) neurodegeneration (ND) portfolio, including the EPAD project. This comprehensive resource is an integral part of Neuronet’s endeavour to…
The European Prevention of Alzheimer’s Dementia (EPAD) project is very pleased to announce the external release of its final dataset for all researchers from over the world. The final dataset is called Version.IMI (V.IMI) as it represents all the data collected and processed during the IMI period of EPAD. A key achievement of the EPAD…
A conference blog about the 13th Clinical Trials on Alzheimer’s Disease (CTAD) conference which took online, from 4-7 November 2020, has been published on the AlzForum website. The article mentions EPAD and can be read below: EPAD had been supported for five years by the Innovative Medicines Initiative (IMI), which is funded jointly by the…
A key achievement of the EPAD project was the establishment of a Longitudinal Cohort Study (LCS) that has screened over 2,000 participants and collected a wide range of cognitive, clinical, neuroimaging and biomarker data to help further our understanding of the early stages of Alzheimer’s disease. “We aim to ensure that this precious collection of…
The Alzheimer’s Disease Data Initiative (ADDI) has launched its Alzheimer’s disease (AD) Workbench, a cloud-based platform for scientists to accelerate discoveries and innovations for AD and related dementias. ADDI is a new global effort that aims to advance AD innovation by connecting researchers with the data needed to generate insights and inform the development of improved…
The EPAD team has published a new paper entitled “Prediction of Alzheimer’s disease biomarker status defined by the ‘ATN framework’ among cognitively healthy individuals: results from the EPAD longitudinal cohort study” in the journal Alzheimer’s Research Therapy. In this paper, authors from the University of Oxford and the Alzheimer Center Amsterdam tested the predictive utility of…
The Alzheimer’s Disease Data Initiative (ADDI) aims to move Alzheimer’s disease (AD) innovation further and faster by connecting researchers with the data they need to generate insights to inform development of new, better treatments and diagnostic tools for AD and related dementias. We are pleased that ADDI is supporting the EPAD project. In 2016, EPAD…
